Calidi Biotherapeutics grants 16,000 stock options
Calidi Biotherapeutics, Inc. (CLDI) reported that Chief Scientific Officer Antonio Fernandez Santidrian received a grant of 16,000 incentive stock options under the company’s 2023 Equity Incentive Plan.
Rhea-AI Filing Summary
Calidi Biotherapeutics, Inc. (CLDI) reported that Chief Scientific Officer Antonio Fernandez Santidrian received a grant of 16,000 incentive stock options under the company’s 2023 Equity Incentive Plan. The options have an exercise price of $1.36 per share and expire on August 17, 2036.
According to the vesting schedule, 25% of the options vest on the one-year anniversary of August 17, 2026, and the remaining 75% vest in equal monthly installments over 36 months, subject to continued service. The filing notes this grant does not include incentive stock options previously granted to the reporting person.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 16,000 shares
Grant/Award
1 txn
Insider
Fernandez Santidrian Antonio
Role
Chief Scientific Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Options (right to buy) F1, F2 | 16,000 | -- | -- |
Holdings After Transaction:
Stock Options (right to buy) — 16,000 contracts (Direct)
Footnotes (2)
- F1. Pursuant to the Issuer's 2023 Equity Incentive Plan (the "2023 Plan"), on August 17, 2026 (the "Grant Date"), the Reporting Person was granted 16,000 incentive stock options (the "Options") at an exercise price of $1.36, which is equal to the closing price of the Issuer's common stock on the Grant Date. 25% of the options will vest upon the one (1) year anniversary of 08/17/2026, and the remaining 75% of the options will vest in 1/36th installments on a monthly basis, subject to the Reporting Person's continued service to the Issuer. The Options were granted in a transaction exempt under Rule 16b-3 to the Reporting Person.
- F2. Does not include the incentive stock options previously granted to the Reporting Person.
Key Figures
Options Granted: 16,000 options
Exercise Price: $1.36 per share
Post-transaction Options Position: 16,000 options
+3 more
6 metrics
Options Granted
16,000 options
Incentive stock options granted to Chief Scientific Officer on August 17, 2026
Exercise Price
$1.36 per share
Equal to the closing price of CLDI common stock on the August 17, 2026 grant date
Post-transaction Options Position
16,000 options
Reported holding after this grant; excludes previously granted incentive stock options
Vesting Cliff
25%
Vests on the one-year anniversary of August 17, 2026, subject to continued service
Remainder Vesting
75%
Vests in 1/36th monthly installments after the one-year anniversary, subject to continued service
Option Expiration
August 17, 2036
Expiration date of the granted incentive stock options
Key Terms
incentive stock options, 2023 Equity Incentive Plan, Rule 16b-3
3 terms
incentive stock options financial
"the Reporting Person was granted 16,000 incentive stock options (the "Options")"
Incentive stock options are a type of employee stock option that gives eligible workers the right to buy company shares at a fixed price later on, often below future market value. They matter to investors because they align employee incentives with company performance, can dilute existing ownership when exercised, and create potential tax advantages for option holders if certain holding-time rules are met — think of them as a coupon to buy stock at today’s price with extra tax rules attached.
2023 Equity Incentive Plan financial
"Pursuant to the Issuer's 2023 Equity Incentive Plan (the "2023 Plan")"
Rule 16b-3 regulatory
"The Options were granted in a transaction exempt under Rule 16b-3"
Rule 16b-3 is a Securities and Exchange Commission regulation that exempts certain routine, pre-approved transactions by company insiders from automatic liability for short-term trading profits. It acts like a safe harbor: if an insider follows a formal plan or the board approves specific transactions in advance, profits from buying and selling company stock within six months are not automatically reclaimed. Investors care because the rule clarifies when insider trades are permissible and reduces uncertainty about potential clawbacks.
FAQ
What equity award did CLDI grant to Chief Scientific Officer Antonio Fernandez Santidrian?
Calidi Biotherapeutics (CLDI) granted 16,000 incentive stock options to Chief Scientific Officer Antonio Fernandez Santidrian. These options were issued under the 2023 Equity Incentive Plan, providing the right to buy common stock at a fixed exercise price if vesting conditions are met.
What is the exercise price of the new stock options reported for CLDI?
The new incentive stock options for CLDI’s Chief Scientific Officer have an exercise price of $1.36 per share. This price equals the closing price of Calidi’s common stock on the August 17, 2026 grant date, as disclosed in the footnotes.
How do the CLDI stock options granted on August 17, 2026 vest over time?
For CLDI, 25% of the granted options vest on the one-year anniversary of August 17, 2026. The remaining 75% then vest in 1/36th monthly installments, contingent on the executive’s continued service with Calidi Biotherapeutics.
When do the newly granted CLDI stock options expire?
The incentive stock options granted by CLDI to its Chief Scientific Officer expire on August 17, 2036. After this expiration date, any unexercised options become invalid and can no longer be used to purchase Calidi common stock.
Are the 16,000 CLDI options the executive’s only stock options?
No. The filing states that the 16,000 incentive stock options reported do not include incentive stock options previously granted. This means the executive may hold additional option awards that are not part of this specific Form 4 transaction entry.
Were the CLDI option grants made under a Rule 10b5-1 trading plan?
The filing indicates the grant was made under the 2023 Equity Incentive Plan and is exempt under Rule 16b-3. The document-level 10b5-1 checkbox is marked false, so these awards are not described as made under a Rule 10b5-1 trading plan.
AI-generated analysis. How Rhea-AI works. Not financial advice.
